We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome.
- Authors
William Lester, J.; Fernandes, A.W.
- Abstract
Pioglitazone monotherapy and combinations were assessed in patients with type 2 diabetes and metabolic syndrome (Adult Treatment Panel III criteria) from four worldwide randomised, multicentre, double-blind studies. Patients were treated for 52 weeks with pioglitazone (PIO,n = 1040), sulphonylurea (SU,n = 535) or metformin (MET,n = 500) PIO + SU (n = 277) or MET + SU (n = 273); or PIO + MET (n = 286) or SU + MET (n = 275). Pooled week 52 glycaemic and lipid changes were compared using analysis of covariance. Haemoglobin A1c decreased significantly with pioglitazone compared with sulphonylurea (p < 0.05). Fasting, 2- and 3-h plasma glucose, insulin and homeostasis model assessment for insulin resistance decreased significantly with pioglitazone compared with other monotherapies (p < 0.05) and decreased significantly with PIO + MET compared with SU + MET (p < 0.05). Pioglitazone, alone and with metformin, improved lipid components of diabetic dyslipidaemia more than did their respective comparison groups. Pioglitazone was associated with weight increase. In conclusion, pioglitazone provided effective glycaemic control and lipid profile improvements in patients with type 2 diabetes and metabolic syndrome.
- Publication
International Journal of Clinical Practice, 2005, Vol 59, Issue 2, p134
- ISSN
1368-5031
- Publication type
Academic Journal
- DOI
10.1111/j.1742-1241.2005.00459.x